Small Molecules

21 Oct 2018 Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
21 Oct 2018 NANOBIOTIX: positive phase II/III results for NBTXR3 in soft tissue sarcoma presented at ESMO
21 Oct 2018 Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
19 Oct 2018 Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer (mCRPC) at ESMO 2018 Congress
19 Oct 2018 Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to
19 Oct 2018 CHMP issues a positive opinion for Bevespi Aerosphere for the treatment of chronic obstructive pulmonary disease
19 Oct 2018 Menarini Progresses Into the Clinic With MEN1611, a PI3K Inhibitor for the Treatment of HER2 Positive Metastatic Breast Cancer
19 Oct 2018 Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
19 Oct 2018 AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
19 Oct 2018 Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
19 Oct 2018 Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
19 Oct 2018 Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint
18 Oct 2018 ORYZON receives approval to start CLEPSIDRA: a Phase IIa clinical trial in Small Cell Lung Cancer with Iadademstat (ORY-1001)
18 Oct 2018 Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin
18 Oct 2018 Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the North American Cystic Fibrosis Conference (NACFC)
16 Oct 2018 Abide Therapeutics Announces Initiation of Phase 2 Clinical Trial of ABX-1431 in Tourette Syndrome
16 Oct 2018 eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination Trial to Evaluate eFFECTOR's Tomivosertib (eFT508) with KEYTRUDA® (pembrolizumab) for Metastatic Triple Negative Breast Cancer
16 Oct 2018 Karuna Announces First Patient Dosed in Phase 2 Study of Lead Product Candidate KarXT for the Treatment of Schizophrenia
16 Oct 2018 PellePharm Presents Updated Data from Two Phase 2 Studies Demonstrating the Potential of Patidegib Topical Gel to Treat Basal Cell Carcinomas in Patients with Gorlin Syndrome and in Patients with Non-Gorlin Sporadic BCCs
16 Oct 2018 PolyPid Begins Phase 2 Study to Assess Safety and Efficacy of D-PLEX100 in Prevention of Abdominal Surgical Site Infections
16 Oct 2018 SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
16 Oct 2018 Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer
16 Oct 2018 Retrotope Presents Data Demonstrating Arrest of Disease Progression with Treatment of RT001 in Patients with Infantile Neuroaxonal Dystrophy (INAD)
14 Oct 2018 BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea
14 Oct 2018 Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up